MYCIT
Live / Registered — Registered (as of 25 Aug 2020)
What this means for you
Registered since 25 Aug 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79267601
- Registration number
- 6132512
- Mark type
- Stylized text
- Filed
- 01 Jul 2019
- Published for opposition
- 09 Jun 2020
- Registered
- 25 Aug 2020
- Attorney of record
- Catherine C. Miller
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products for the treatment of cancer, in particular based on nucleic acids and/or proteins; personalised patient-specific medicinal products, in particular based on nucleic acids and/or proteins, namely, pharmaceutical preparations for treatment of cancer diseases, autoimmune diseases, and infectious diseases
- Class 009 — Scientific and electric apparatus: Scientific apparatuses and instruments, namely, next generation sequencers for laboratory research use; software algorithms, namely, downloadable software programs for use in analyzing next generation sequencer data, in particular for the detection and collection of mutations in cancer patients
- Class 010 — Medical apparatus: High-throughput analytical instruments, in particular instruments for next-generation sequencing (NGS) for medical issues, as well as for gene expression profiling and for the detection of epigenetic changes, namely, high throughput genome and exome gene sequencers for medical use
- Class 042 — Scientific and technological services: Medical research and development in the field of cancer immunotherapy, in particular research and development in the field of human and veterinary medical diagnostics and treatment by means of molecular-biological, genetic, biotechnological and/or bioinformatic methods, in particular by means of next-generation sequencing; Scientific laboratory services and scientific research services featuring diagnostics of tumour markers for personalised treatment
- Class 044 — Medical, beauty and agricultural services: Medical, veterinary-medical and pharmaceutical advisory services, in particular in the selection of suitable treatments for cancer diseases of all kinds; Medical services, namely, performance of analyses and treatments as part of personalised cancer immunotherapy; Medical services for the treatment of cancer, namely, provision of treatments based on nucleic acids and/or checkpoint inhibitors
Owner
- BioNTech SE, DE
- BioNTech SE, DE
- BioNTech SE, DE
Prosecution history
- 12 Mar 2026 — NEW REPRESENTATIVE AT IB RECEIVED
- 25 Aug 2025 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 15 Apr 2022 — NEW REPRESENTATIVE AT IB RECEIVED
- 19 Dec 2020 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 02 Dec 2020 — FINAL DISPOSITION NOTICE SENT TO IB
- 01 Dec 2020 — FINAL DISPOSITION PROCESSED
- 25 Nov 2020 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 25 Aug 2020 — REGISTERED-PRINCIPAL REGISTER
- 09 Jun 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 09 Jun 2020 — PUBLISHED FOR OPPOSITION
- 05 Jun 2020 — NOTIFICATION PROCESSED BY IB
- 20 May 2020 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 20 May 2020 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 20 May 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 May 2020 — APPROVED FOR PUB - PRINCIPAL REGISTER